Significance of the fluid-blood interface in intracranial hematomas in anticoagulated patients.
Six patients receiving anticoagulant medication who had laboratory evidence of impaired hemostasis as manifested by laboratory parameters exceeding the therapeutic range developed intracranial hemorrhages. None of these patients had a history of preceding trauma. None of the 6 anticoagulated had CNS symptoms prior to initiation of anticoagulant medication. Within the intracranial hemorrhage there was a fluid-blood interface in these 6 patients; this finding was seen only in hemorrhages in anticoagulated patients. In 3 cases the fluid-blood interface changed to a homogeneous hyperdense lesion when adequate hemostasis was achieved. In one case there were multiple hemorrhages and in the other there was a solitary intracerebral hemorrhage.
Weisberg
L A
LA
Department of Neurology and Psychiatry, Tulane Medical School, New Orleans, LA 70112.
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D001812:Blood-Brain Barrier / Q000187:drug effects*; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D005260:Female; D006408:Hematoma, Subdural / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D013300:Streptokinase / Q000009:adverse effects; D013924:Thrombophlebitis / Q000188:drug therapy; D014057:Tomography, X-Ray Computed
D000925:Anticoagulants; D006493:Heparin; D013300:Streptokinase